Adenovirus Clinical Trial
— Adeno-betaOfficial title:
A Double-blind, Placebo-controlled Randomized Study Comparing the Effectiveness of a Single Dose of Betamethasone vs Placebo in Children With Symptomatic Adenovirus Infection
The goal of this double-blind, Placebo-controlled Randomized Study is to assess if a single dose of betamethasone in children with febrile adenoviral infection works well in achieving an early fever regulation. The experimentation is conducted to answer this question: "Can betamethasone help reduce fever more quickly in a child with viral adenovirus infection? "The secondary objective is to assess if the child's overall clinical conditions improve more rapidly (reduced sore throat, quicker return to regular eating) and a reduction in the incidence and duration of hospitalizations.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | April 1, 2026 |
Est. primary completion date | January 15, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Months to 6 Years |
Eligibility | Inclusion Criteria: - Body Temperature measured with an axillary or ear thermometer >= n 37.5°C, persisting for a minimum of 6 hours and a maximum of 5 days. - Clinical presentation consistent with pharyngo-tonsillar infection by Adenovirus, including At least one of the following symptoms: pharyngodonidae /asthenia/nausea/vomiting/diarrhea/cough/rhinorrhea/abdominal pain/otalgia and at least one of the following signs: pharyngeal hyperemia with or without pharyngo-tonsillar exudate/inflammation of the upper or lower airways/lymphadenopathy/skin rash.- - Positive result on the antigen test for Adenovirus performed with the "Biosensor" rapid swab. - Negative result on the swab for Group A Streptococcus (SBEGA), if deemed necessary following McIsaac criteria - Informed consent form for participation in the study signed by the parent(s) or legal guardian. Exclusion Criteria: - Adequate dosage of betamethasone in the 48 hours prior. - Underlying chronic illness associated with an increased risk of unusual or severe adenoviral infection. - Inability to tolerate oral medications. - Documented allergy or any other known contraindication to Bentelan 0.5mg® medication.-Patients on chronic therapy with anticholinesterases, salicylates, nonsteroidal anti-inflammatory drugs, thiazides, furosemide, amphotericin, xanthines (theophylline), antidiabetic drugs, insulin, cyclosporine, ritonavir, ketoconazole, acetylsalicylic acid, phenytoin, phenobarbital, ephedrine, rifampicin, anticoagulants. - Subacute or chronic conditions requiring a higher equivalent dose of betamethasone or known primary or secondary adrenal insufficiency. - Transfer to another hospital for any reason. - Parents who are unable to understand the proposed study or cannot reliably participate in phone follow-up due to significant language barriers. - Participation in another study involving an experimental drug within the 30 days prior to and during the current study. |
Country | Name | City | State |
---|---|---|---|
Italy | Ospedale Infantile Regina Margherita | Torino |
Lead Sponsor | Collaborator |
---|---|
A.O.U. Città della Salute e della Scienza |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients with a sustained fever resolution at 24 hours from randomization | The proportion of patients achieving sustained fever resolution at 24 hours from is the proportion of patients with a a body temperature <37.5°C at 18 and 24 hours from randomization. | at 18 and 24 hours from randomization | |
Secondary | Pharyngeal-tonsillar pain level in patients younger than 36 months | According to the patient age, the pharyngeal-tonsillar pain level of the child will be measured by the FLACC (Face, Legs, Activity, Cry, Consolability) scale in patients younger than 36 months.
FLACC mean value 5 points on ten. |
from the date of randomization, up to 72 hours | |
Secondary | Hospitalization | The proportion of patients admitted following emergency access. | from date of randomization until the date of discharge from emergency department, up to 72 hours | |
Secondary | Duration of hospitalization (among those hospitalized), measured in days | Number of days from admission date to discharge date. | from date of randomization until the date of discharge,up to 72 hours | |
Secondary | Cumulative incidence of fever resolution | Cumulative incidence of fever resolution is measured from randomization until the fever resolution confirmed by measurement at the subsequent timepoint; patients without fever resolution within the time of the last fever assessment are censored at this time. | from date of randomization to 72 hours from randomization | |
Secondary | Fever duration | Time from randomization until the first measurement with Body Temperature<37.5°C | from date of randomization until 72 hours from randomization | |
Secondary | Pharyngeal-tonsillar pain level in patients older than 36 months | According to the patient's age, the pharyngeal-tonsillar pain level of the child was measured by the Faces Pain Rating Scale (Wong-Baker Scale) in patients with age more or equal to 36 months. | from the date of randomization, up to 72 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02984280 -
Specific Respiratory Infections as Triggers of Acute Medical Events
|
N/A | |
Recruiting |
NCT03665675 -
Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
|
Early Phase 1 | |
Completed |
NCT01431326 -
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
|
||
Recruiting |
NCT03266627 -
Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
|
Phase 2 | |
Not yet recruiting |
NCT03325517 -
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics
|
N/A | |
Not yet recruiting |
NCT06392451 -
LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia
|
N/A | |
Recruiting |
NCT05183490 -
R-MVST Cells for Treatment of Viral Infections
|
Phase 1 | |
Completed |
NCT04056546 -
Interest of Rapid Typing in Adenovirus Infections.
|
||
Withdrawn |
NCT00448994 -
Adenovirus and Fungal Load in Pediatric Stem Cell Transplant Patients
|
N/A | |
Enrolling by invitation |
NCT06027879 -
Anti-viral T-cell Therapy by Gamma Capture
|
Phase 1/Phase 2 | |
Recruiting |
NCT02779439 -
Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation
|
Phase 1 | |
Terminated |
NCT02420080 -
A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304
|
N/A | |
Active, not recruiting |
NCT01945814 -
Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)
|
Phase 1 | |
Completed |
NCT01535885 -
Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV
|
Phase 1 | |
Terminated |
NCT03339401 -
The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation
|
Phase 2 | |
Withdrawn |
NCT01584037 -
Adenovirus Vaccine Pregnancy Registry
|
N/A | |
Withdrawn |
NCT03532035 -
Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia
|
Phase 2 | |
Recruiting |
NCT02008812 -
Ad Sensor-based Real-time Diagnosis of Adenovirus
|
N/A | |
Active, not recruiting |
NCT04364178 -
Viral Specific T-Lymphocytes to Treat Adenovirus or CMV
|
Phase 1/Phase 2 | |
Recruiting |
NCT05664126 -
Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation
|
Phase 2 |